Vicplas International (SGX:569) Stock Based Compensation: S$0.0 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vicplas International Stock Based Compensation?

Vicplas International SGX:569 Stock Based Compensation is S$0.0 Mil as of Jan. 2026. The stock has 5 warning signs investors should review.

Vicplas International's Stock Based Compensation for the six months ended in Jan. 2026 was S$0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 was S$0.0 Mil.

Vicplas International Stock Based Compensation Related Terms

Vicplas International Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vicplas International's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicplas International Stock Based Compensation Chart

Vicplas International Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.29 0.36 0.12 0.03

Vicplas International Semi-Annual Data
Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25 Jan26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.02 0.01 0.01

Vicplas International Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.0 Mil.

What does a Stock Based Compensation of S$0.0 Mil mean?
Vicplas International (SGX:569) has a Stock Based Compensation of S$0.0 Mil as of Jan. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vicplas International and its competitors.
Is Vicplas International's Stock Based Compensation too high?
Vicplas International's current Stock Based Compensation is S$0.0 Mil.
How does Vicplas International's Stock Based Compensation compare to ABT and SYK?
Vicplas International's Stock Based Compensation of S$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vicplas International and its competitors. Vicplas International's current Stock Based Compensation is S$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.07 — trading 39.1% below its estimated fair value. The current Stock Based Compensation is S$0.0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vicplas International (SGX:569), the current Stock Based Compensation is S$0.0 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicplas International Business Description

Address 35 Joo Koon Circle, Singapore, SGP, 629110
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.